CagriSema
A once-weekly fixed combination of the amylin analog cagrilintide and semaglutide delivering roughly 22.7% average body-weight loss in trials. It is not yet approved, with regulatory filing expected in late 2026.
- Half-life
- 7.0 d
- Out of system
- ~5 weeks
- Route
- Subcutaneous
- Level
- Intermediate
Long-acting — weekly dosing keeps levels steady. After the last dose, roughly 97% has cleared in ~5 weeks (five half-lives) — the window that matters for washouts, bloodwork and surgery.
What CagriSema is used for
- Combines cagrilintide and semaglutide for roughly 22.7% average body-weight loss in trials
- Dual amylin and GLP-1 action may improve satiety beyond a GLP-1 alone
- Once-weekly subcutaneous dosing fits an established injection routine
How it's typically used
Trial range: titrated to 2.4 mg subcutaneously once weekly (fixed cagrilintide plus semaglutide combination), as reported in Phase 3 studies.
What to watch for
- GI side effects and GLP-1 class thyroid and gallbladder warnings apply
- Trial titration schedules are specific and adverse events cluster during dose escalation
- Not approved anywhere; investigational with regulatory filing expected late 2026
About GLP-1 & weight loss
- What they are
- Incretin analogues — GLP-1 and dual/triple agonists. They slow stomach emptying and act on appetite centres in the brain, so you eat less without white-knuckling it.
- How they're run
- One subcutaneous shot a week for most, on the same day each week. Doses climb in steps every four weeks; that slow titration is what keeps side effects tolerable.
- What to watch
- Nausea, constipation, and reflux are near-universal in the first month. Muscle is lost alongside fat unless you keep protein high and keep lifting. Tell any surgeon or anaesthetist you are on one.
Full guide
CagriSema: A Tracking Guide for a Cagrilintide and Semaglutide Combination
A harm-reduction look at CagriSema, an investigational amylin-plus-GLP-1 combination not yet approved, and what would be worth tracking.
Other glp-1 & weight loss
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.